

## **Product datasheet**

# anti-UACA mouse monoclonal, AE-5, purified

#### Short overview

**Cat. No.** 691532

 Quantity
 1 ml (100 μg/ml)

 Concentration
 100 μg/ml

### **Product description**

HostMouseAntibody TypeMonoclonalIsotypeIgG1 kappaCloneAE-5

Immunogen Nuclei of myeloid leukemia biopsy cells

**Formulation** PBS with 0.02% sodium azide

UniprotID Q9BZF9 (Human), Q8CGB3 (Mouse)

Synomym Uveal autoantigen with coiled-coil domains and ankyrin repeats, UACA, KIAA1561

Conjugate Unconjugated

**Purification** Affinity chromatography

Storage 2-8°C

Intended use Research use only
Application FACS, ICC/IF, IHC, WB

Reactivity Human, Mouse

### **Applications**

Flow Cytometry (FACS) 1-2  $\mu$ g/million cells in 0.1 ml, fix cells in 4% PFA for 10 min at 4°C,

permeabilize with 0.2% saponin or digitonin for 15 min at 4°C

 Immunocytochemistry (ICC)
 1:100-1:200 (0.5-1.0 μg/ml)

 Immunohistochemistry (IHC) - frozen
 1:50-1:100 (1-2 μg/ml)


 Western Blot (WB)
 1:50-1:100 (1-2 μg/ml)

#### Background

UACA (Uveal Autoantigen with Coiled-coil domains and Ankyrin repeats) is a 1,416 amino acid nuclear membrane protein. It was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also later identified as Nucling, a mRNA differentially expressed in F9 embryonal carcinoma cells, and that it is up-regulated during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1-pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.

Positive control: HeLa or 293T cells. Highly expressed in skeletal muscle, heart, kidney and pancreas. Also expressed in epidermal melanocytes, eye muscles and thyroid follicular cells.

# **Product images**



Western blot with A549 cell lysate